Literature DB >> 14501285

Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis?

Dan Fontaine1, Winston Parkhill, Wenda Greer, Noreen Walsh.   

Abstract

Whether partial regression of a primary melanoma has an adverse impact on prognosis is controversial. As an indirect mechanism of addressing this question we drew a correlation between the histopathological characteristics of 107 cutaneous melanomas and the presence of sub-clinical metastasis in corresponding sentinel lymph nodes. Partial regression of the primary tumor, defined as focal replacement of the lesion by a scar, unrelated to a previous biopsy, was observed in 20 (19%) cases in the group as a whole. Excluding cases in which an accurate Breslow thickness of the primary melanoma could not be established and/or the presence of a capsular nevus was detected in the sentinel node, a total of 97 remained. Seventeen cases (Breslow thickness 0.63-9.7; mean 2.4 mm) showed partial regression and 80 (Breslow thickness 0.25-7.00; mean 1.8 mm) were devoid of regression. Of the 17 cases with regression 5 (29%) had nodal metastasis (by histopathology and/or molecular analysis) and of the 80 cases without regression 23 (29%) had nodal metastasis (by one or both evaluations). Our data reveals no association between partial regression of the primary melanoma and sentinel node involvement by the disease. The Breslow thickness proved to be the only significant independent variable related to nodal metastasis. Of interest, ulceration of the primary lesion was significantly associated with nodal disease on univariate, but not on multivariate, analysis. While acknowledging that the cohort size may lack the statistical power to demonstrate subtle associations, our data supports the known relevance of tumor thickness and ulceration to regional lymph node metastasis and thereby, to outcome of melanoma in its early stages, but fails to support a similar role for partial regression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501285     DOI: 10.1097/00000372-200310000-00002

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  12 in total

Review 1.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Journal:  Semin Immunopathol       Date:  2011-01-31       Impact factor: 9.623

Review 2.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

Review 3.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

4.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

5.  High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Authors:  Sook Jung Yun; Phyllis A Gimotty; Wei-Ting Hwang; Peter Dawson; Patricia Van Belle; David E Elder; Rosalie Elenitsas; Lynn Schuchter; Paul J Zhang; DuPont Guerry; Xiaowei Xu
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

6.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

7.  The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.

Authors:  Armando Pérez-Torres; Jesús Vera-Aguilera; Juan Carlos Hernaiz-Leonardo; Eduardo Moreno-Aguilera; Diego Monteverde-Suarez; Carlos Vera-Aguilera; Daniel Estrada-Bárcenas
Journal:  Cancer Biother Radiopharm       Date:  2013-07-10       Impact factor: 3.099

8.  Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma Group.

Authors:  João Pedreira Duprat; Eduard René Brechtbülh; Bianca Costa de Sá; Mauro Enokihara; Jose Humberto Fregnani; Gilles Landman; Marcus Maia; Felice Riccardi; Francisco Alberto Belfort; Alberto Wainstein; Luciana F Moredo; Higino Steck; Miguel Brandão; Marcelo Moreno; Eduardo Miranda; Ivan Dunshee de Oliveira Santos
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

9.  Metastatic melanoma with spontaneous complete regression of a thick primary lesion.

Authors:  Hasan Khosravi; Andressa L Akabane; Allireza Alloo; Rosalynn M Nazarian; Genevieve M Boland
Journal:  JAAD Case Rep       Date:  2016-12-03

10.  Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors.

Authors:  Sabina Zurac; Monica Neagu; Carolina Constantin; Mirela Cioplea; Roxana Nedelcu; Alexandra Bastian; Cristiana Popp; Luciana Nichita; Razvan Andrei; Tiberiu Tebeica; Cristiana Tanase; Virginia Chitu; Constantin Caruntu; Mihaela Ghita; Catalin Popescu; Daniel Boda; Bogdan Mastalier; Nicoleta Maru; Claudiu Daha; Bogdan Andreescu; Ioan Marinescu; Adrian Rebosapca; Florica Staniceanu; Gabriela Negroiu; Daniela A Ion; Dragana Nikitovic; George N Tzanakakis; Demetrios A Spandidos; Aristidis M Tsatsakis
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.